Marked Truncal Acne Response to Sarecycline Monotherapy in Different Ethnicities

Main Article Content

Angela Moore
Stephen Moore
Luke Moore
Ayman Grada
Stephen Tyring

Keywords

acne

Abstract

N/A

References

1. Del Rosso JQ, Stein-Gold L, Lynde C, Tanghetti E, Alexis AF. Truncal Acne: A
Neglected Entity. J Drugs Dermatol. 2019;18(12):205-1208.

2. Tan J, Beissert S, Cook-Bolden F, et al. Impact of facial and truncal acne on
quality of life: A multi-country population-based survey. JAAD International.
2021;3:102-110. doi:10.1016/j.jdin.2021.03.002

3. Bunick CG, Keri J, Tanaka SK, et al. Antibacterial Mechanisms and Efficacy of
Sarecycline in Animal Models of Infection and Inflammation. Antibiotics (Basel).
2021;10(4):439. doi:10.3390/antibiotics10040439

4. Moore A, Green LJ, Bruce S, et al. Once-daily oral sarecycline 1.5 mg/kg/day
is effective for moderate to severe acne vulgaris: Results from two identically
designed, phase 3, randomized, double-blind clinical trials. Journal of drugs in
dermatology : JDD. 2018;17(9):987-996.

5. Del Rosso JQ, Stein Gold L, Baldwin H, et al. Management of Truncal Acne
With Oral Sarecycline: Pooled Results from Two Phase-3 Clinical Trials. J
Drugs Dermatol. 2021;20(6):634-640. doi:10.36849/JDD.2021.620

Most read articles by the same author(s)

1 2 3 > >>